Clinical Trials Logo

Retinitis Pigmentosa clinical trials

View clinical trials related to Retinitis Pigmentosa.

Filter by:

NCT ID: NCT03281005 Recruiting - Clinical trials for Retinitis Pigmentosa

Development of Visual Function Evaluation Method

Start date: September 12, 2017
Phase: N/A
Study type: Observational

The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient

NCT ID: NCT03252847 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR)

Start date: July 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial of AAV2 vector for patients with X-linked retinitis pigmentosa (XLRP)

NCT ID: NCT03248388 Recruiting - Clinical trials for Retinitis Pigmentosa

Argus II/ORCAM Device Study

Start date: August 2017
Phase: N/A
Study type: Interventional

This study is being done to determine if wearable text-to-speech (TTS) and visual pattern recognition (VPR) technology can be used to extend the capabilities of the Argus II to allow patients to read and recognize faces and objects. The Argus II retinal prosthesis can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition. The FDA has approved the Argus II as a humanitarian device. Present-day wearable text-to-speech converters are also capable of object and face recognition. Such systems have been developed to assist with these tasks in patients with severe low-vision. ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.

NCT ID: NCT03146078 Recruiting - Clinical trials for Usher Syndrome, Type 2A

Rate of Progression in USH2A Related Retinal Degeneration

Start date: June 2017
Phase: N/A
Study type: Observational

The overall goal of this project is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39).

NCT ID: NCT03116113 Recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa

Start date: March 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial of AAV-RPGR retinal gene therapy for patients with X-linked retinitis pigmentosa

NCT ID: NCT03078309 Not yet recruiting - Clinical trials for Retinitis Pigmentosa

The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients

Start date: September 2017
Phase: Early Phase 1
Study type: Interventional

Medical Marijuana is used widely, and its effects on the visual system and the function of the retina have not been investigated thoroughly. Some evidence suggests that cannabinoids may be beneficial in certain degenerative diseases of the retina. The purpose of the study is 1. To determine whether cannabis derivatives affect the visual functions in healthy adults 2. To examine the effect of cannabis derivatives on the retina of retinitis pigmentosa patients

NCT ID: NCT03073733 Recruiting - Clinical trials for Retinitis Pigmentosa

Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

Start date: March 1, 2017
Phase: Phase 2
Study type: Interventional

This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to sham treated controls in a cohort of adult subjects with RP.

NCT ID: NCT03063021 Recruiting - Clinical trials for Retinitis Pigmentosa

The FIGHT-RP1 Study

Start date: February 15, 2017
Phase: Phase 1
Study type: Interventional

Retinitis Pigmentosa (RP) is a devastating eye disease and at present there are no known treatment options that can alter the rate of vision loss. In a series of studies in animal models, the effects of exposing cones in the periphery of the retina to a large excess of oxygen results in progressive oxidative damage to cone photoreceptors and cone cell death. Compared to control patients, those with RP showed significant reduction in the reduced to oxidized glutathione ratio (GSH/GSSG) in aqueous humor and a significant increase in protein carbonyl content. This demonstration of oxidative stress and oxidative damage in the eyes of patients with RP, suggests that oxidative damage-induced cone cell death in animal models of RP may translate to humans with RP and support the hypotheses that (1) potent antioxidants will promote cone survival and function in patients with RP and (2) aqueous GSH/GSSG ratio and carbonyl content on proteins provide useful biomarkers of disease activity in this patient population. Orally administered N-Acetylcysteine (NAC) has been found to be a particularly effective antioxidant that promotes prolonged cone survival and maintenance of cone function in a mouse model of RP. There is good rationale to test the effect of NAC in patients with RP. The first step is to do test different dosing regimens to identify the lowest dose that is able restore aqueous GSH/GSSG ratio and reduce carbonyl adducts on aqueous proteins. In patients with Idiopathic Pulmonary Fibrosis, polymorphisms within the TOLLIP gene were found to influence outcomes of NAC-treated patients. The product of the TOLLIP gene, toll-interacting protein, is an inhibitory adaptor protein downstream of toll-like receptors, mediators of innate and adaptive immunity. The identification of the influence of TOLLIP polymorphisms on the effect of NAC in Idiopathic Pulmonary Fibrosis provides rationale for collecting DNA and genotyping the same single nucleotide polymorphisms (SNPs) in the current trial. In addition to this candidate gene genetic analysis, patient RNA will be collected and banked for future transcriptome analysis. The rationale for this is to identify gene expression changes that modify disease progression in RP. There is substantial variability in rate of progression among patients with RP. A patient who loses all vision early in life can have a sibling with the same mutation who maintains vision into advanced age. This suggests that modifier genes can have a major impact on cone survival. This study will test the hypothesis that the level of expression of gene products that contribute to the antioxidant defense system may influence cone cell death and hence the rate of loss of visual field. It is also possible that gene expression differences may contribute to differences in response to NAC. For these reasons collecting RNA samples from patients will allow next generation sequencing in the future to understand the transcriptome background on which the study intervention has been performed.

NCT ID: NCT03057496 Not yet recruiting - Glaucoma Clinical Trials

Collision Warning Device for Blind and Visually Impaired

Start date: November 2017
Phase: N/A
Study type: Interventional

This study evaluates a novel collision warning device to help people with severe vision impairment or blindness avoid collisions with obstacles. The main hypothesis to be tested is that the device reduces the number of collisions with obstacles in everyday activities.

NCT ID: NCT03011541 Recruiting - Glaucoma Clinical Trials

Stem Cell Ophthalmology Treatment Study II

Start date: January 2016
Phase: N/A
Study type: Interventional

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.